The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

• Auteurs principaux: Wen Yin (Auteur), Tianqi Xu (Auteur), Mohamed Altai (Auteur), Maryam Oroujeni (Auteur), Jie Zhang (Auteur), Anzhelika Vorobyeva (Auteur), Olga Vorontsova (Auteur), Sergey V. Vtorushin (Auteur), Vladimir Tolmachev (Auteur), Torbjörn Gräslund (Auteur), Anna Orlova (Auteur)
• Format: Livre
• Publié: MDPI AG, 2021-11-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the infl...